Nuvectis (NVCT): Rasio rega marang pendapatan

Nuvectis Pharma, Inc. (NVCT) attracts leading scientists through high autonomy and ambitious R&D goals. The company's price-to-sales ratio confirms this trajectory, where the current status equals . Environmental policy is based on the principles of "green chemistry" and safe disposal. Since there are no commercial products, the financial position relies exclusively on the external raising of investment capital.

NVCT Multiplikator P/S Nuvectis Pharma, Inc. (04.07.2022 - 14.11.2026)

Nuvectis Pharma, Inc. (NVCT) - rincian metrik lan laporan keuangan

- kuotasi saiki lan rata-rata prakiraan nilai:

Rega bursa Nuvectis Pharma Inc.|NVCT - Bagan rega target

- data kapitalisasi bursa:

Nilai pasar Nuvectis Pharma|NVCT - Nilai Total Perusahaan

- statistik nilai buku emiten:

Nilai Aset Bersih saben Saham Nuvectis Pharma|NVCT - Kapitalisasi Buku|Rasio Nilai Pasar marang Ekuitas nuvectis.com|NVCT - Gunggung Aset Perusahaan

- indikator beban kredit lan likuiditas emiten:

Utang marang Modal Nuvectis Pharma, Inc.|NVCT - Rasio utang jangka dawa marang ekuitas|Rasio tanggungan utang jangka cendhak marang modal Nuvectis Pharma|NVCT - Gunggung utang perusahaan|Utang marang modal buku Nuvectis Pharma, Inc|NVCT - Utang jangka dawa perusahaan|Silihan lan utang jangka cendhak perusahaan Nuvectis Pharma|Likuiditas darurat nuvectis.com

- data bathi lan kelipatan valuasi:

NVCT - Bathi resik perusahaan|Penghasilan resik sing dikarepake Nuvectis Pharma, Inc.|NVCT - Pangali P/E|Pangali Forward P/E Nuvectis Pharma, Inc|NVCT - Rasio rega marang bathi tumrap wutah|Rasio nilai perusahaan marang bathi operasional sadurunge panyusutan Nuvectis Pharma, Inc.|NVCT - Bathi operasional sadurunge ngurangi amortisasi|Bathi resik saben siji saham sajrone rolas wulan pungkasan Nuvectis Pharma|NVCT - Bathi saben saham sajrone rolas wulan pungkasan|Wutah bathi saben saham taun-ka-taun sajrone 12 wulan pungkasan nuvectis.com|NVCT - Wutah bathi resik saben saham ing taun iki|Prakiraan wutah bathi kanggo taun ngarep Nuvectis Pharma, Inc.

- rincian pendapatan lan dodolan emiten:

NVCT - Dodolan perusahaan|Prakiraan pendapatan perusahaan Nuvectis Pharma|NVCT - Multiplikator P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Nuvectis Pharma, Inc

Ringkesan analitik perusahaan:Nuvectis Pharma

The scale of Nuvectis Pharma, Inc. (NVCT) business and the market recognition of its developments are clearly reflected in this market cap-to-revenue ratio. This multiple compares the total asset value with annual sales volume, determining the innovation premium within an independent product cycle, where stable demand for pharmaceuticals makes this indicator a key measure of the company's fundamental stability and investment potential.

Perusahaan pesaing

INCY - Rega marang dodolan|Rasio rega marang pendapatan hutch-med.com HCM|Nuvation Corp - Rasio rega marang pendapatan|DAWN - Rasio rega marang pendapatan|Rega marang dodolan Monopar Therapeutics|INBX: Multiplikator P/S|Multiplikator rega marang pendapatan I-Mab IMAB|Kapitalisasi marang pendapatan FENC|Rega marang dodolan Heron Therapeutics, Inc. HRTX|Kapitalisasi marang pendapatan CHRS (Coherus BioSciences, Inc)|CRBP (Corbus Pharmaceuticals Holdings) - Rasio kapitalisasi pasar marang pendapatan|Cardiff Oncology - Kapitalisasi marang pendapatan|Kapitalisasi marang volume dodolan BYSI (BeyondSpring)|BioAtla - Multiplikator P/S|Rasio kapitalisasi pasar marang pendapatan LIXT (Lixte Biotechnology Holdings)|CTXR: Multiplikator P/S|Rega marang dodolan cellectar.com (CLRB)|Rasio rega marang pendapatan BioLineRx|CANF: Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S APRE|Multiplikator P/S Kazia Therapeutics Ltd (KZIA)|Rasio rega marang pendapatan Silexion Therapeutics Corp. SLXN|NCNA (nucana.com) - Rasio rega marang dodolan|CMRX: Kapitalisasi marang pendapatan|Rega marang dodolan Cyclacel|GTHX: Multiplikator P/S|Kronos Bio Corporation (KRON) - Multiplikator P/S|KTRA (kintara.com) - Multiplikator P/S|Rasio kapitalisasi marang pendapatan ONCT (Oncternal Therapeutics)|Rasio rega marang pendapatan Portage Biotech (PRTG)